CytoSorbents Highlights Upcoming Presentations at EACTS 2023

Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry - Seite 4

Other Key Presentations at EACTS

In addition to the STAR Registry analysis, another study was selected for presentation entitled, “Antithrombotic drug removal during off-pump coronary artery bypass grafting using hemoadsorption” highlighting the successful use of CytoSorb, in conjunction with a simple hemoperfusion machine, to prophylactically remove Brilinta or Xarelto during off-pump CABG surgery. According to the study investigators, Mair et al., stated, “Decoupling of the hemoadsorber from the cardiopulmonary bypass machine will open new future indications in various medical specialties (e.g. trauma, neurosurgery) and in emergency patients on antithrombotic medication.”

CytoSorbents will also host a satellite research symposium on Friday, October 6, 2023 at 12:15-13:30 CET.

Hemoadsorption with CytoSorb after 10 years – Where do we stand?
Chairs: Sandra Lindstedt (Sweden) and Piotr Suwalski (Poland)

• The Paris experience – Which patients benefit most?
  Guillaume Lebreton, France
• The Oslo experience – Removal of antithrombotics to reduce complications and costs
  Gry Dahle, Norway
  
• The Essen experience – Hemoadsorption in aortic surgery
  Heinz Jakob, Germany

*These trademarks are owned by their respective pharmaceutical manufacturers: Eliquis (Pfizer, BMS), Xarelto (Bayer, Janssen), Brilinta/Brilique (AstraZeneca), Plavix (BMS, Sanofi), Effient (Daiichi Sankyo, Eli Lilly), Savaysa/Lixiana (Daiichi Sankyo), and Pradaxa (Boehringer Ingelheim)

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb, is approved in the European Union and distributed in 75 countries worldwide with more than 212,000 devices cumulatively used as of Q2 2023. CytoSorb is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses seen in the ICU and cardiac surgery that can lead to massive inflammation, organ failure, and a high risk of patient death. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively. CytoSorb is also E.U. approved to remove the blood thinners, ticagrelor and rivaroxaban, during cardiothoracic surgery to reduce the risk of perioperative bleeding. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.